|
For the first time, tagatose has been certified as Plant-Based and Vegetarian. Tagatose is an ultra-low glycemic index sugar substitute found in tiny quantities in plants such as apples, pineapples, and the sap of a tree related to the cocoa tree. But because tagatose is found in nature is such small amounts, for commercial purposes it must be made from other food materials. In the case of other companies, tagatose is made from dairy-derived lactose and, therefore, is not plant-based. That other process involves multiple separation, conversion and purification steps that result in a high-cost product that suffers from scalability challenges. In contrast, Bonumose’s unique method enzymatically converts plant starch (e.g., potato, cassava, corn, etc.) to tagatose in a high-yield, high-purity process. Bonumose’s tagatose is made from a globally abundant food commodity (starch), using the same kind of equipment that is used to make common, inexpensive sweeteners. This results in cost-savings for food companies and their consumers. Based on application materials prepared by Bonumose’s Director, Regulatory & Nutrition, Dr. Karen Weikel, Bonumose’s tagatose achieved certification under FoodChain ID’s “Vegetarian and Plant-Based Product” Standard. Dr. Weikel has been responsible for many other certifications for Bonumose’s tagatose, such as Non-GMO (aka “butterfly stamp”), Ketogenic, Kosher (Orthodox Union), and Halal (Ifanca), and played an important role in Bonumose’s Safe Quality Foods certification. Tagatose does not increase blood glucose or insulin. Tagatose is beneficial for dental/oral health. It has 62% fewer calories than sugar. Tagatose acts similarly to dietary fiber in the gut where beneficial bacteria use it to produce healthy short-chain fatty acids. Meanwhile, tagatose retains a taste and flavor nearly indistinguishable from sugar (sucrose), with 92% of the sweetness, and a “cookability” that more closely resembles sugar than other sugar substitutes do. Bonumose’s first tagatose production facility is located near Charlottesville, Virginia. Tagatose is available for bulk purchase through ASR Group. |
|
|
|
News
Recent News
06/02/2026
TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed
TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and …
06/02/2026
Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development
Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing, …
06/02/2026
GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row
The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business …